Q4 2024 Avanos Medical Inc Earnings Call Transcript

Feb 26, 2025 / 02:00PM GMT

Release Date Price: €14 (-6.04%)

Transcript 10-K8-K

Key Points

Positve

Avanos Medical Inc (AVNS) delivered a strong fourth quarter with solid performance in its enteral feeding franchise, achieving organic sales growth of 5% compared to the previous year.
The company successfully completed its obligations related to the sale of its respiratory health business, marking a key milestone in its three-year transformation process.
Avanos Medical Inc (AVNS) served over 2 million patients in 2024 through its enteral feeding portfolio and pain management solutions, highlighting its impact in providing essential healthcare services.
The company reported a 31% increase in adjusted diluted earnings per share for the full year, demonstrating significant financial improvement.
Avanos Medical Inc (AVNS) maintained a strong balance sheet with $108 million of cash on hand and $135 million of debt outstanding, providing strategic flexibility for future growth opportunities.

Negative

The company recorded a non-cash impairment charge of approximately $437 million due to the fair value of its single company reporting unit being below its carrying value.
Avanos Medical Inc (AVNS) experienced uneven performance in its pain management and recovery portfolio, with normalized organic sales down approximately 3% for the quarter.
The HA portfolio faced pricing pressure, leading to a forecasted 20% decrease in HA revenue for the full year, impacting overall financial performance.
The company anticipates a temporary pause in margin improvement for 2025 due to challenging market conditions, currency headwinds, and other global macroeconomic factors.
Avanos Medical Inc (AVNS) expects its Corporate and Other segment to decline over 20% in 2025, reflecting ongoing challenges in certain product categories.

Operator

Good morning ladies and gentlemen. Welcome to the Avanos fourth quarter 2024 earnings call.

(Operator Instructions)

This call is being recorded on Wednesday, February 26, 2025.

I would now like to turn the conference over to Mr. Scott Galovan, Senior Vice President of Strategy and Corporate Development. Please go ahead.

Scott Galovan

Avanos Medical Inc - Senior Vice President of Strategy and Corporate Development

Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos 2024 fourth quarter and full year Earnings conference call. Presenting today will be Michael Greiner, Interim CEO.

Michael will review our fourth quarter and full year results, the current business environment as well as provide an update on our transformation efforts. Additionally, Michael will provide our 2025 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, avanos.com.

As a reminder, our comments today contain

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.